• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Obituary Notice: Russell “Russ” Haines

    Abenza Chooses North Carolina for New Biologics Manufacturing Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Arkema Recruits Dotmatics as its R&D Digitalization Partner
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    PCI Pharma Services

    Alcami

    Almac Group

    Adare Pharma Solutions

    Syngene
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Quotient Sciences

    Alcami

    Adare Pharma Solutions

    Reed-Lane

    Emergent BioSolutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Two Strikes, Two Outs, or Time Out? Inhalation for Systemic Effect

    The challenges of using the lung as a portal for the treatment of systemic conditions

    Two Strikes, Two Outs, or Time Out? Inhalation for Systemic Effect
    Related CONTENT
    • Injectables: The New Oral?
    • Capsugel and Pulmatrix Enter Collaboration
    • G3, Sanofi Partner to Identify Heart Disease Targets
    • MannKind Ends Afrezza License with Sanofi
    • Capsugel Launches enTRinsic Drug Delivery Platform
    Tugrul Kararli, Kurt Sedo, Josef Bossart, PHARMACIRCLE10.11.16
    It shouldn’t be that hard to develop pulmonary administered formulations of pharmaceuticals for the treatment of systemic conditions. For centuries a variety of active agents, notably tobacco, marijuana and opium, have been delivered via the pulmonary route with exceptional efficacy and, one could argue, relatively limited safety and tolerability issues in the absence of prolonged chronic use. Why does the delivery of prescription pharmaceuticals to the lung for systemic effect present such a challenge for the pharmaceutical industry? To use a baseball metaphor, do the well-reported business challenges of Mannkind’s Afrezza represent strike two, or a second out, in the development of meaningful inhaled pharmaceuticals for the treatment of systemic disease?

    It’s not a new challenge
    The challenges that have faced both Afrezza, and Exubera before it, are to some degree obscured by the too easy assumption that it is strictly a challenge of delivering macromolecules. While insulin, a protein of 51 amino acids and a molecular weight of 5,808 Daltons, is a relatively large molecule, many other products with much smaller molecular weights, easily delivered orally, have failed to gain approval. Among those few that have received approval, none have been widely adopted.

    Local delivery for local and locoregional effect
    There are dozens of approved pharmaceuticals administered to the lung by a variety of methods and devices. What the majority of these agents have in common is their use to treat local lung related conditions. These conditions range from asthma, to chronic obstructive pulmonary disease (COPD), to infectious disease, to lung cancer. The types of agents delivered by the pulmonary route to treat these conditions range from small molecule bronchodilators, antimuscarinics and steroids to the relatively larger antibiotics and much larger recombinant proteins. Common to these applications is the expectation that these inhaled pharmaceuticals will have only a local, rather than systemic, effect. In fact, any type of systemic exposure is generally looked upon with disfavor, especially with the use of corticosteroids for the management of asthma and COPD.

    The pulmonary route is also used for the treatment of certain locoregional conditions impacting the lung and heart, most notably pulmonary hypertension where there is a complex interaction of pulmonary and cardiac dynamics. Delivery via the lung provides for somewhat selective delivery of relatively toxic agents to the heart and lung that would create safety and tolerability issues if delivered orally or intravenously where distribution is much wider and higher doses are required to achieve desired tissue levels in the lung and heart.

    Why systemic delivery via the lung?
    There are two major reasons underlying the development of inhalation formulations targeting systemic delivery: improved efficacy and convenience. The logic for the improving efficacy concerns the ability to provide a faster onset of action, something comparable to intravenous administration, without a needle. This seems to be the reasoning behind the ongoing and past development of a variety of pulmonary formulations of well-characterized CNS agents, notably fentanyl for the treatment of acute onset pain, and loxapine for agitation. The convenience benefit aims to improve patient acceptance by substituting inhalation for injection. This is certainly a desirable option with the chronic administration of macromolecules where injection, either subcutaneously or intravenously, is the only practical route of effective delivery.

    Afrezza, MannKind’s inhaled insulin product, it seems was intended to deliver on both these needs by substituting inhalation for subcutaneous injection. More recently though, Mannkind in their reboot of Afrezza, has been touting the benefits of a more rapid onset of action, realizing perhaps that the simple subcutaneous injection of insulin, even multiple times a day, is not nearly as onerous as it once was.

    A rapid onset of action with no need for an injection was also imagined for Alexza’s Adasuve, an inhaled formulation of loxapine intended for the treatment of agitation associated with schizophrenia. Approved in 2012 it has struggled to capture sales, despite having a reasonably elegant and effective delivery system.

    A not too surprising relative success of systemic delivery via the lung has been nicotine inhalers. Approved for smoking cessation using a cartridge-based system, these inhalers actually deposit most of the nicotine in the buccal region with less than 5% reaching the lung. Formally pulmonary formulations, these nicotine inhalers might better be considered as buccal delivery systems.

    Despite all of the interest and investment in developing inhaled analgesics for the management of breakthrough cancer pain and other acute pain indications, the only approved inhalation product for pain is Penthrox (methoxyflurane), a halogenated ether repurposed for acute pain management. Penthrox is used to treat pain in an acute trauma setting under the supervision of a medical professional using a proprietary inhalation device.

    Considering the lack of approved inhalation products for systemic effect it may be that the challenges faced by Exubera and Afrezza are less related to the task of delivering effective doses of a larger molecule to the lung than the challenge of providing a meaningful competitive benefit. Different doesn’t qualify as better.

    It should be mentioned that there are also a number of general anesthetic gases administered by the pulmonary route that have a profound systemic effect. These agents, though, are administered using sophisticated in-hospital devices that are unsuited for outpatient use.

    Efficacy, safety, convenience and price
    It’s possible to estimate the real-world potential of a pharmaceutical by considering its proposed competitive product profile in terms of its ESCP (efficacy, safety, convenience and pricing) attributes. Without efficacy it is unlikely that a product will receive regulatory approval, although products can vary in their degree of efficacy. With an assumption of efficacy, physicians and patients generally pay considerable attention to safety and tolerability. Beyond efficacy and safety, the next level of concern is convenience of administration, including dosing frequency and method of administration. This is where oral, transdermal and even inhaled products have a substantial advantage over injectables in the outpatient setting. Lastly, if all things are equal in terms of efficacy, safety and convenience, the prescribing decision is usually made on the basis of price.
    These terms of reference may explain why inhaled pharmaceuticals intended for systemic treatment, especially inhaled insulin, have received little traction with patients, physicians and patients.
    • Efficacy: We can safely assume by virtue of regulatory approvals that inhaled insulin is efficacious for the approved indications.
    • Safety: While inhaled insulin may be safe by regulatory standards, it seems that physicians do not consistently believe that it is as safe as injectable. There are any number of arguments supporting and questioning the safety and tolerability of inhaled insulin, but any product that is to be administered chronically to the lung needs to have no questions in this area.
    • Convenience: This should be an obvious advantage for Afrezza; no needles. But convenience comes at the expense of additional pulmonary testing, prior to starting therapy and then every few months to ensure that lung function is not being compromised. The testing, while not overly complex, is not an office procedure conducted in most general practitioner offices. Patient convenience, no needle, is balanced by physician and patient inconvenience, additional testing. Dosing with Afrezza also requires dose titration that is not simple or obvious with the available dosing packages. At the same, time injected insulin products are increasingly offering more sophisticated pen and delivery devices that reduce the sting, and the fear, of self-injection.
    • Pricing: Insulin therapy is not inexpensive and it appears that Exubera at the time, and now Afrezza, are priced at a small premium to the injectables, including the pen formulations.
    Adding it all up the balance doesn’t seem to sufficiently favor Afrezza enough to push patients to switch to inhaled insulin, or physicians to prescribe it more often.
    A similar analysis can be performed for Alexza’s Adasuve. Although indicated for acute rather than chronic use in the inpatient setting, a higher price and a requirement for patient supervision seem to outweigh any benefit in terms of convenience and injection avoidance.

    Pipelines past and pipelines future
    So what does past performance mean for the development inhalation pipeline, especially products targeted to systemic and locoregional treatment?

    In comparison with marketed products the development pipeline ratios for Local and systemic products (Table 2) pretty much parallel the ratio for Local products, with a somewhat greater emphasis on locoregional-inhaled products. Among registration stage products, the systemic product is a metered dose formulation of dihydroergotamine for migraine. The locoregional product is nebulized nitric oxide for pulmonary hypertension.

    Examining the development pipeline in terms of targeted indications, Table 3 reveals that the majority of effort, is targeted to a small number of indications, notably respiratory—asthma, COPD, bronchospasm, and respiratory distress syndrome—and a variety of infectious lung diseases.

    Neurological applications top the list of systemic indications in the pipeline and range from migraine to Parkinson’s to epilepsy. There is only a single product identified as being in development for diabetes, Dance-501, last reported as being Phase II testing.

    Pulmonary hypertension is the top indication by far for product development using the lung to affect a locoregional therapeutic benefit.

    Strike two, two outs or time out?
    Do the challenges of inhaled insulin close the door on the opportunity for inhaled macromolecules, or the use of the lung as a portal for the delivery of any systemic acting pharmaceutical? The pipeline data, Table 4, seems to suggest that pulmonary delivery of macromolecules continue to be of significant interest, with almost a quarter of all pipeline products falling into the larger molecular weight class. But, the majority of these products are being developed for Local therapeutic benefit, not locoregional or systemic. Perhaps then the industry is taking a time out to rethink the potential of using the lung for the systemic delivery irrespective of molecular size. There may be better options that carry less risk. 

    Given the relative lack of success of Exubera and Afrezza, along with their decade long development timelines and billion dollar costs, it is likely that the pharmaceutical industry is taking a time out to reconsider the opportunity of macromolecule delivery for systemic effect. None of the top selling macromolecules, all delivered in the outpatient setting by self-injection, are seen to be in development for pulmonary delivery. Nonetheless, there continues to be considerable interest in the delivery of macromolecules to the lung, but for local and locoregional applications. It may take the success of future small molecule products providing systemic benefits to lure the industry back to developing macromolecules anything more than local and locoregional applications.


    Tugrul Kararli is president and founder of PharmaCircle. Before founding the firm in 2003 Tugrul’s industry experience included 18 years at Searle/Pharmacia where he was involved with pharmaceutics, product development and drug delivery activities. As chairman of the global drug delivery technology team Dr. Kararli was responsible for the identification, planning and execution of drug delivery technology strategies for marketed and development products.

    Kurt Sedo is vice president at PharmaCircle and responsible for product development and client services. Prior to joining PharmaCircle in 2003, Kurt held various positions and responsibilities within pharmaceutical sciences and analytical development departments at Searle/Pharmacia.

    Josef Bossart serves as executive editor with PharmaCircle. Jo has decades of experience in the biopharmaceutical industry having held senior sales, marketing, operational and business development positions within Big Pharma and specialty pharma companies. More recently he has focused on analysis and strategy development related to drug delivery companies and products with numerous published articles and conference presentations.
    Related Searches
    • Drug Development
    • Drug Delivery
    Suggested For You
    Injectables: The New Oral? Injectables: The New Oral?
    Capsugel and Pulmatrix Enter Collaboration Capsugel and Pulmatrix Enter Collaboration
    MannKind Ends Afrezza License with Sanofi MannKind Ends Afrezza License with Sanofi
    G3, Sanofi Partner to Identify Heart Disease Targets G3, Sanofi Partner to Identify Heart Disease Targets
    Capsugel Launches enTRinsic Drug Delivery Platform Capsugel Launches enTRinsic Drug Delivery Platform
    PlaqueTec Appoints Tim Brears as CEO PlaqueTec Appoints Tim Brears as CEO
    DefiniGEN Licences Lung Stem Cell Technology from University of Cambridge DefiniGEN Licences Lung Stem Cell Technology from University of Cambridge
    3  Sanofi-Aventis 3 Sanofi-Aventis
    BMS, uniQure Enter Cardiovascular R&D Pact BMS, uniQure Enter Cardiovascular R&D Pact
    MannKind Earns $50M Sanofi Milestone MannKind Earns $50M Sanofi Milestone
    Sanofi, MannKind Enter Global Afrezza Pact Sanofi, MannKind Enter Global Afrezza Pact
    AstraZeneca to Buy Respiratory Drug Company, Amirall AstraZeneca to Buy Respiratory Drug Company, Amirall
    Afrezza Gets Panel Date Afrezza Gets Panel Date
    DiaMedica Completes MAD Trial DiaMedica Completes MAD Trial
    FibroGen Begins IPF Trial Enrollment FibroGen Begins IPF Trial Enrollment

    Related Features

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Trends in Solid Oral Dosage Delivery

      Trends in Solid Oral Dosage Delivery

      Capsule demand continues to rise due to this delivery system’s versatility.
      Anita Solanki, Milind Biyani and Jnanadeva Bhat, PhD , ACG Capsules 03.01.21

    • Drug Delivery | Parenterals
      Injectable Drug Delivery Trends

      Injectable Drug Delivery Trends

      How medication trends are driving the shift to patient-friendly drug delivery systems.
      Peter Soelkner, Managing Director, Vetter 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Oral Solids:   Market & Technology Trends

      Oral Solids: Market & Technology Trends

      Oral solids remain the preferred route of drug delivery due to their cost-effectiveness, ease of manufacturing, and patient-friendly dose form options.
      Tim Wright, Editor, Contract Pharma 03.01.21


    • Drug Delivery | Solid Dosage/Creams/Ointments
      Medicated Chewing Gum: A Modern Oral Drug Delivery System

      Medicated Chewing Gum: A Modern Oral Drug Delivery System

      Development and manufacture of medicated chewing gum continues to gain momentum.
      Rukayat Adedeji, Contributing Writer 03.01.21

    • Drug Delivery
      Inhaled Drug Delivery Technology

      Inhaled Drug Delivery Technology

      The success of any new inhaled medicine relies in a large part on the correct combination of formulation and device technology being chosen for its delivery.
      Dr. Sandy Munro, Vice President – Pharmaceutical Development, Vectura 01.27.21

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20


    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20

    • Drug Delivery
      Wet Wipes Increased Prevalence in Drug Development

      Wet Wipes Increased Prevalence in Drug Development

      A number of factors including patient preference are driving the growth of wet wipes in pharma.
      John Waddell, Business Development Director – Pharma, PDI Contract Manufacturing 10.14.20

    • Drug Development | Drug Discovery | R&D
      R&D Outsourcing Trends

      R&D Outsourcing Trends

      Highly specialized drug products and capacity needs drive increased reliance on contract service providers.
      Kristin Brooks, Managing Editor, Contract Pharma 10.14.20


    • Drug Development | Preclinical Outsourcing
      Preclinical Planning for Successful Drug Development

      Preclinical Planning for Successful Drug Development

      When the preclinical pressure is on, appropriate planning can make sure timelines are achievable.
      Mingyi Trimble, WuXi AppTec 09.09.20

    • APIs | Drug Development | Risk Management
      Small-Molecule Drug Development: Advantages of an Integrated, Phase-Based Approach

      Small-Molecule Drug Development: Advantages of an Integrated, Phase-Based Approach

      Small-molecule drug development has become more complex and challenging, leading to greater reliance on CDMOs.
      Sarah Bethune, Cambrex 09.09.20

    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Managing Editor 09.09.20


    • Drug Delivery
      Not Your Father’s Oral Thin Film

      Not Your Father’s Oral Thin Film

      A look at how oral film drug delivery is evolving.
      Rodolphe Obeid, Vice President of Operations, IntelGenx 06.04.20

    • Drug Delivery | Regulatory Affairs
      Regulatory Overhaul for Medical Devices

      Regulatory Overhaul for Medical Devices

      Implications for the pharmaceutical industry.
      Elizma Parry, Director, Global Clinical Practice, Maetrics 06.04.20

    • Drug Delivery
      CEO Spotlight: Will Downie

      CEO Spotlight: Will Downie

      Vectura’s chief executive talks trends in the inhaled-drug market, and the company’s transition into a CDMO
      Tim Wright, Editor, Contract Pharma 04.01.20

    Trending
    • Thermo Fisher Acquires PPD For $17.4B
    • Ensuring Pharma Manufacturing Quality
    • Bristol Myers Squibb Expands At Cambridge Crossing
    • Abenza Chooses North Carolina For New Biologics Manufacturing Site
    • Amgen Completes Five Prime Acquisition
    Breaking News
    • Bristol Myers Squibb Expands at Cambridge Crossing
    • Amgen Completes Five Prime Acquisition
    • Sartorius Expands in the UK
    • Obituary Notice: Russell “Russ” Haines
    • Abenza Chooses North Carolina for New Biologics Manufacturing Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    AstaReal Astaxanthin Ingredient Receives U.S. Patent Approval
    Study on Kemin’s DailyZz Botanical Blend Uncovers Sleep Quality, Next-Day Performance Benefits
    FDA’s Dr. Cara Welch Opening Speaker at the 9th AHPA Botanical Congress
    Coatings World

    Latest Breaking News From Coatings World

    Jebsen & Jessen, Innospec Sign Distribution Agreement
    IGL Coatings Announces Partnership in Finland
    Axalta Schedules 1Q 2021 Earnings Conference Call
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Iterative Scopes Announces IBD-Focused Scientific Advisory Board
    Vicarious Surgical, D8 Holdings Corp. Combine Operations in $1.1 Billion Deal
    FDA Grants De Novo Clearance to Medtronic’s GI Genius Model
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Bristol Myers Squibb Expands at Cambridge Crossing
    Amgen Completes Five Prime Acquisition
    Sartorius Expands in the UK
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Former L’Oréal Exec Joins Glossier
    Lancôme Reveals New Global Sustainability Program
    First-Ever Skincare Line Focuses on Iron To Prevent Aging
    Happi

    Latest Breaking News From Happi

    Fragrance Creators Association Celebrates P&G Executive
    Evonik Highlights Solutions for Malodor Reduction
    P&G Emphasizes Small Actions at Home To Be More Sustainable
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    TLMI reveals Eugene Singer Award winners at Virtual Spring Summit
    Monadnock Paper Mills joins SGP
    ACTEGA helps converter reach sustainability goals
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Albaad to Add Natural-Based Line in Israel
    First Quality to Discontinue Tampon Operations
    Jessup Installs New Era Coating and Laminating Line
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    BioMagnetic Sciences Names President and CEO
    Mainstay Medical Launches ReActiv8 in Australia
    Biogennix Rolls Out Agilon Strip Bone Graft
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence
    LG Display Cuts Down CO2-eq Emissions by 3 Million Tons in 2020
    European Commission's Innovation Radar Acknowledges 3 ARMOR Innovations

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login